Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma | Zendy

Megan Dupuis | Zendy; Barry Paul | Zendy; Gavin Loitsch | Zendy; Parker Mathews | Zendy; Daniel Feinberg | Zendy; Ian Barak | Zendy; Zhiguo Li | Zendy; Sascha A. Tuchman | Zendy; Yubin Kang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma

Author(s) -

Megan Dupuis,

Barry Paul,

Gavin Loitsch,

Parker Mathews,

Daniel Feinberg,

Ian Barak,

Zhiguo Li,

Sascha A. Tuchman,

Yubin Kang

Publication year - 2020

Publication title -

jco oncology practice

Language(s) - English

Resource type - Journals

eISSN - 2688-1535

pISSN - 2688-1527

DOI - 10.1200/jop.19.00517

Subject(s) - multiple myeloma , medicine , point of care , chart , disease , retrospective cohort study , oncology , pathology , statistics , mathematics

PURPOSE: We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG).METHODS: We calculated the difference between a patient’s total serum protein and albumin as a point-of-care test for assessing disease status in MM.RESULTS: GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw.CONCLUSION: Our study has important implications in the care of MM, particularly in countries/areas with limited resources.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research